Mediphage Bioceuticals is a genetic medicine company spun out of the University of Waterloo in Canada, focused on developing SAFE, EFFECTIVE, and ACCESSIBLE gene delivery platforms to unlock the therapeutic power of personalized, redoseable, genetic medicine.
Mediphage Bioceuticals Inc. was formed as a spin off company from the University of Waterloo in Ontario, Canada.
Mediphage Bioceuticals closes its seed round to develop proof of concept and perform early stage efficacy studies.
Mediphage Bioceuticals successfully develops its DNA Ministring production and targeting technology. Mediphage also completes early stage concept and efficacy studies.
Mediphage Bioceuticals moves to the MaRS Innovation Center located in Toronto, Ontario. Mediphage Bio is now entering late stage safety and efficacy studies and is beginning to manufacture DNA Ministrings in compliance with cGMP manufacturing practices.
Mediphage Bioceuticals has developed DNA ministrings (msDNA), the safest transgene delivery vector on the market that does not compromise effectiveness and can be produced at a fraction of the cost of competing solutions.
msDNA is a SAFE, EFFECTIVE and highly ACCESSIBLE nonviral gene delivery vector. Unlike conventional viral and nonviral vectors msDNA’s topology as a linear covalently closed “string” makes it both stable and the safety tool for gene delivery.
msDNA is generated through Mediphage Bioceuticals’ patented E. coli “in vivo” production system. Our system is highly scalable because it requires a simple temperature shift to generate large-scale quantities.
msNDA is the only vector capable of protecting individuals from harmful mutations in the chromosome by selectively inducing cell death upon harmful integration.
msDNA contains no immunostimulatory components which allows for enhanced repeated administration.
With the highest safety profile across viral and nonviral vectors, ministring DNA enhances the transition of current genetic engineering technology into true personalized genetic medicine.
Current Applications of msDNA
msDNA are an efficient, customizable and redosable vector for ex vivo and in vivo gene therapies, cell therapies and gene editing.
Our msDNA is currently being evaluated by big pharmaceutical companies and biotechnology companies looking to develop in vivo DNA vaccines, cell therapies using T/-B engineering, and therapeutics using the CRISPR system.
Dr. Roderick Slavcev,
Founder & CEO, HBSc, PhD, MBA, MRSB, C.Biol
Associate Professor, Pharmaceutical Sciences
Professor, Business & Entrepreneurship School of Pharmacy, University of Waterloo
Chartered Biologist, Royal Society of Biology
Director of R&D, PhD, MSc
B.W. Pearson Research Medal (2014)
University of Waterloo School of Pharmacy Award of Excellence (2013)
Chief Operating Officer
MA - International Relations
BMath - Computer Science (Bioinformatics)